Floatz logo

Cabiralizumab

Peripheral T Cell Lymphoma

University of Michigan Rogel Cancer Centermonoclonal_antibodyPhase 2Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
73/ 100

Competitive context

136 Active assets in the Peripheral T Cell Lymphoma cohort.

Asset / SponsorPhaseRating
Inno-206
BeBetter Med Inc
Phase 4BBB
PREDNISONE TABLETS
Tarapeutics Science Inc.
Phase 4BBB
Pralatrexate
Peking University People's Hospital
Phase 4BBB
(+)-VINCRISTINE
BeBetter Med Inc
Phase 4BBB
Cyclophosphamide
Tarapeutics Science Inc.
Phase 4BBB

View all 50 →

Same molecule, other indications

Cabiralizumab is also rated in:

malignant pancreatic neoplasmDormant
B
Indicative ·
60 / 100
View asset →
cancerDormant
CCC
Indicative ·
50 / 100
View asset →
pancreatic neoplasmDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →